A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
Published Online: 2019-08-?
Journal: Annals of OncologyLoading...
Authors: A. Schneeweiss•B. Rautenberg•B.V. Sinn•C. Denkert•C. Hanusch•C. Jackisch•E.-M. Grischke•G. von Minckwitz•H. Tesch•J. Furlanetto•J. Huober•J. Thomalla•J.-U. Blohmer•K. Engels•K. Rhiem•K. Weber•M. Rezai•M. Untch•N. Burchardi•P.A. Fasching•S. Kümmel•S. Loibl•W.D. Schmitt
